title: Serum lipids, lipoprotein lp(a), and plasminogen activator inhibitor-1 in patients with Turner's syndrome before and during growth hormone and estrogen therapy.
abstract: OBJECTIVE
  To evaluate whether girls with Turner's syndrome have an increased risk for cardiovascular disease due to alterations in their lipoprotein metabolism.
  
  
  METHODS
  Controlled clinical study.
  
  
  METHODS
  Private academic hospital.
  
  
  METHODS
  Fifteen untreated girls with Turner's syndrome were studied initially; 11 of these patients were evaluated further while on therapy.
  
  
  METHODS
  Serum lipids, lipoprotein lp(a), and plasminogen activator (PA) inhibitor-1 were measured before and during 6 months of either GH or estrogen (E) treatment.
  
  
  METHODS
  Serum lipids, lipoprotein lp(a), and PA inhibitor-1 (PAI-1).
  
  
  RESULTS
  Total and low-density lipoprotein (LDL) cholesterol, triglycerides, lipoprotein lp(a), and PA inhibitor-1 levels were normal in Turner's syndrome patients compared with age-matched controls; HDL cholesterol was increased. During GH treatment, a significant decrease in total and LDL cholesterol was noted, whereas lipids, lipoprotein(a), and PA inhibitor-1 levels did not change with E therapy.
  
  
  CONCLUSIONS
  The normal lipoproteins of untreated adolescents with Turner's syndrome, as well as the further decrease of total and LDL cholesterol during GH treatment, would seem to indicate that lipoproteins do not increase the cardiovascular risk of these girls.
authors.affiliation: Unidad de Endocrinologia Pediatrica, Hospital de Clinicas Caracas, Venezuela.
authors.forename: R
authors.initials: R
authors.lastname: Lanes
authors.forename: P
authors.initials: P
authors.lastname: Gunczler
authors.forename: A
authors.initials: A
authors.lastname: Palacios
authors.forename: O
authors.initials: O
authors.lastname: Villaroel
mesh_terms: D000293:Adolescent; D002648:Child; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D004966:Estrogens, Conjugated (USP) / Q000627:therapeutic use*; D005260:Female; D013006:Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D008055:Lipids / Q000097:blood*; D017270:Lipoprotein(a) / Q000097:blood*; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood*; D014424:Turner Syndrome / Q000097:blood* / Q000188:drug therapy
chemical_list: D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D004966:Estrogens, Conjugated (USP); D008055:Lipids; D017270:Lipoprotein(a); D017395:Plasminogen Activator Inhibitor 1; D013006:Growth Hormone